Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biktarvy switch effect on bone density in African women on DMPA
NCT03916328Phase 4Unknown
- Sponsor
- MU-JHU Research Collaboration
- Start
- Dec 2019
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bictegravir + emtricitabine + tenofovir alafenamide in osteoporosis, sponsored by MU-JHU Research Collaboration. Status: unknown.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT03916328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03916328.